Granules India’s arm clears audit by US health regulator

22 Jul 2021 Evaluate

Granules India’s wholly owned foreign subsidiary -- Granules Pharmaceuticals, Inc. (GPI) has cleared an audit by the US health regulator. The company had undergone a Pre-Approval Inspection (PAI) audit by the U.S. Food and Drug Administration (USFDA) from June 21, 2021 to June 25, 2021. The audit is a pre-approval inspection for three of its applications filed from this facility. The FDA issued two minor observations during the audit.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

579.00 14.05 (2.49%)
27-Jan-2026 12:03 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1635.00
Dr. Reddys Lab 1242.60
Cipla 1308.45
Zydus Lifesciences 891.95
Lupin 2143.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×